Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs CYP 001 (Primary) ; Methylprednisolone (Primary) ; Prednisone (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Cynata Therapeutics; FUJIFILM Corporation
- 10 Aug 2023 Planned End Date changed from 31 Mar 2026 to 31 Dec 2026.
- 10 Aug 2023 Planned primary completion date changed from 30 Jun 2024 to 30 Apr 2025.
- 10 Aug 2023 Status changed from not yet recruiting to recruiting.